Latest news
{{'2026-10-20T13:00:00Z' | dateFormatFilter}}
Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting
{{'2026-10-02T20:53:57Z' | dateFormatFilter}}
Novo provides update on the denecimig Biologics License Application (BLA) in the US
{{'2026-10-01T10:45:00Z' | dateFormatFilter}}
Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
